Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease

Y. Wang, Y. Ogawa, M. Dogru, M. Kawai, Y. Tatematsu, M. Uchino, N. Okada, A. Igarashi, A. Kujira, H. Fujishima, Shinichiro Okamoto, J. Shimazaki, Kazuo Tsubota

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

We investigated the effect of 0.05% topical cyclosporine (Cys) on the ocular surface and tear functions in dry eye patients with chronic GVHD (cGVHD) in a prospective comparative study. Thirty eyes of 15 patients refractory to baseline treatment were recruited and the patients assigned for topical Cys treatment group (14 eyes of 7 patients) and control group (12 eyes of 6 patients) respectively. Two patients dropped out because of intolerable irritation while using topical Cys eye drops. Visual analog scale symptom scores, corneal sensitivity, Schirmer I test value, tear film break-up time (TBUT), tear evaporation rate and ocular surface vital staining scores were recorded at baseline and at the end of the following one month. Conjunctival impression and brush cytology were performed before and after the treatment. After topical Cys treatment, significant improvements were found in symptom scores, corneal sensitivity, tear evaporation rate, TBUT, vital staining scores, goblet cells density, conjunctival squamous metaplasia grade, inflammatory cell numbers and the MUC5AC expression. Our study suggests that 0.05% topical Cys may be an effective treatment for dry eye patients with cGVHD. The improvements in the ocular surface and tear functions resulted presumably from the decreased inflammation, increased goblet cell density and MUC5AC mRNA expression.

Original languageEnglish
Pages (from-to)293-302
Number of pages10
JournalBone Marrow Transplantation
Volume41
Issue number3
DOIs
Publication statusPublished - 2008 Feb

Fingerprint

Graft vs Host Disease
Tears
Cyclosporine
Goblet Cells
Cell Count
Therapeutics
Staining and Labeling
Ophthalmic Solutions
Metaplasia
Visual Analog Scale
Cell Biology
Prospective Studies
Inflammation
Control Groups
Messenger RNA

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease. / Wang, Y.; Ogawa, Y.; Dogru, M.; Kawai, M.; Tatematsu, Y.; Uchino, M.; Okada, N.; Igarashi, A.; Kujira, A.; Fujishima, H.; Okamoto, Shinichiro; Shimazaki, J.; Tsubota, Kazuo.

In: Bone Marrow Transplantation, Vol. 41, No. 3, 02.2008, p. 293-302.

Research output: Contribution to journalArticle

Wang, Y, Ogawa, Y, Dogru, M, Kawai, M, Tatematsu, Y, Uchino, M, Okada, N, Igarashi, A, Kujira, A, Fujishima, H, Okamoto, S, Shimazaki, J & Tsubota, K 2008, 'Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease', Bone Marrow Transplantation, vol. 41, no. 3, pp. 293-302. https://doi.org/10.1038/sj.bmt.1705900
Wang, Y. ; Ogawa, Y. ; Dogru, M. ; Kawai, M. ; Tatematsu, Y. ; Uchino, M. ; Okada, N. ; Igarashi, A. ; Kujira, A. ; Fujishima, H. ; Okamoto, Shinichiro ; Shimazaki, J. ; Tsubota, Kazuo. / Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease. In: Bone Marrow Transplantation. 2008 ; Vol. 41, No. 3. pp. 293-302.
@article{7bc02db7fa9a4ed1adba84a42cabc425,
title = "Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease",
abstract = "We investigated the effect of 0.05{\%} topical cyclosporine (Cys) on the ocular surface and tear functions in dry eye patients with chronic GVHD (cGVHD) in a prospective comparative study. Thirty eyes of 15 patients refractory to baseline treatment were recruited and the patients assigned for topical Cys treatment group (14 eyes of 7 patients) and control group (12 eyes of 6 patients) respectively. Two patients dropped out because of intolerable irritation while using topical Cys eye drops. Visual analog scale symptom scores, corneal sensitivity, Schirmer I test value, tear film break-up time (TBUT), tear evaporation rate and ocular surface vital staining scores were recorded at baseline and at the end of the following one month. Conjunctival impression and brush cytology were performed before and after the treatment. After topical Cys treatment, significant improvements were found in symptom scores, corneal sensitivity, tear evaporation rate, TBUT, vital staining scores, goblet cells density, conjunctival squamous metaplasia grade, inflammatory cell numbers and the MUC5AC expression. Our study suggests that 0.05{\%} topical Cys may be an effective treatment for dry eye patients with cGVHD. The improvements in the ocular surface and tear functions resulted presumably from the decreased inflammation, increased goblet cell density and MUC5AC mRNA expression.",
author = "Y. Wang and Y. Ogawa and M. Dogru and M. Kawai and Y. Tatematsu and M. Uchino and N. Okada and A. Igarashi and A. Kujira and H. Fujishima and Shinichiro Okamoto and J. Shimazaki and Kazuo Tsubota",
year = "2008",
month = "2",
doi = "10.1038/sj.bmt.1705900",
language = "English",
volume = "41",
pages = "293--302",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease

AU - Wang, Y.

AU - Ogawa, Y.

AU - Dogru, M.

AU - Kawai, M.

AU - Tatematsu, Y.

AU - Uchino, M.

AU - Okada, N.

AU - Igarashi, A.

AU - Kujira, A.

AU - Fujishima, H.

AU - Okamoto, Shinichiro

AU - Shimazaki, J.

AU - Tsubota, Kazuo

PY - 2008/2

Y1 - 2008/2

N2 - We investigated the effect of 0.05% topical cyclosporine (Cys) on the ocular surface and tear functions in dry eye patients with chronic GVHD (cGVHD) in a prospective comparative study. Thirty eyes of 15 patients refractory to baseline treatment were recruited and the patients assigned for topical Cys treatment group (14 eyes of 7 patients) and control group (12 eyes of 6 patients) respectively. Two patients dropped out because of intolerable irritation while using topical Cys eye drops. Visual analog scale symptom scores, corneal sensitivity, Schirmer I test value, tear film break-up time (TBUT), tear evaporation rate and ocular surface vital staining scores were recorded at baseline and at the end of the following one month. Conjunctival impression and brush cytology were performed before and after the treatment. After topical Cys treatment, significant improvements were found in symptom scores, corneal sensitivity, tear evaporation rate, TBUT, vital staining scores, goblet cells density, conjunctival squamous metaplasia grade, inflammatory cell numbers and the MUC5AC expression. Our study suggests that 0.05% topical Cys may be an effective treatment for dry eye patients with cGVHD. The improvements in the ocular surface and tear functions resulted presumably from the decreased inflammation, increased goblet cell density and MUC5AC mRNA expression.

AB - We investigated the effect of 0.05% topical cyclosporine (Cys) on the ocular surface and tear functions in dry eye patients with chronic GVHD (cGVHD) in a prospective comparative study. Thirty eyes of 15 patients refractory to baseline treatment were recruited and the patients assigned for topical Cys treatment group (14 eyes of 7 patients) and control group (12 eyes of 6 patients) respectively. Two patients dropped out because of intolerable irritation while using topical Cys eye drops. Visual analog scale symptom scores, corneal sensitivity, Schirmer I test value, tear film break-up time (TBUT), tear evaporation rate and ocular surface vital staining scores were recorded at baseline and at the end of the following one month. Conjunctival impression and brush cytology were performed before and after the treatment. After topical Cys treatment, significant improvements were found in symptom scores, corneal sensitivity, tear evaporation rate, TBUT, vital staining scores, goblet cells density, conjunctival squamous metaplasia grade, inflammatory cell numbers and the MUC5AC expression. Our study suggests that 0.05% topical Cys may be an effective treatment for dry eye patients with cGVHD. The improvements in the ocular surface and tear functions resulted presumably from the decreased inflammation, increased goblet cell density and MUC5AC mRNA expression.

UR - http://www.scopus.com/inward/record.url?scp=39349110186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39349110186&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1705900

DO - 10.1038/sj.bmt.1705900

M3 - Article

C2 - 17982500

AN - SCOPUS:39349110186

VL - 41

SP - 293

EP - 302

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 3

ER -